ALEMBIC PHARMACEUTICALS LIMITED
₹797.80+₹2.65 (+0.3%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹15,765 Cr
- P/E
- 35.5x
- EV / EBITDA
- 15.2x
- Revenue
- ₹6,033 Cr
- Net margin
- 11.3%
- ROCE
- 18.5%
Price chart
Technical chartScreen technicals →-11.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -3.4%
- 3M
- -0.5%
- 6M
- +5.7%
- 1Y
- -11.4%
- 5Y
- +2.6%
52-week range
Day change +₹2.65 (+0.3%) from ₹795 to ₹798 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in APLLTD, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Maintains healthy dividend payout of 32.0%
Concerns1
- Negative free cash flow (₹409 Cr)
Rule-based from financial data. Not advice.
About the company
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally.
Read moreShow less
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
- Sector
- Healthcare
- Shares outstanding
- 19.7 Cr shares
- ISIN
- INE901L01018
- BSE code
- 533573
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹15,765 Cr
- P/E
- 35.5x
- P/B
- 3.0x
- EV / EBITDA
- 15.2x
- EV / Sales
- 2.7x
- P/S
- 2.7x
- Earnings yield
- 2.8%
- 52-week high
- ₹960.10
- 52-week low
- ₹646.25
Profitability
- Operating margin
- 17.0%
- Net margin
- 11.3%
- EBITDA margin
- 17.5%
- ROE
- 13.6%
- ROCE
- 18.5%
- ROA
- 10.4%
- Dividend payout
- 32.0%
- Tax rate
- 5.0%
- Other income, % of PBT
- 4.4%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹6,033 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 2.7%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 7.3%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,030 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 54.2%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -24.5%
- Net profit CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -7.2%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹773 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 5.9%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹6.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 4.4%
Solvency and efficiency
- Current ratio
- 3.35
- Debt / Equity
- 0.10
- Debt / Assets
- 0.08
- Debt / EBITDA
- 0.48
- Interest coverage
- 18.50
- Financial leverage
- 1.30
- CFO / Net profit
- 1.16
- Cash / Market cap
- 19.7%
- Cash per share
- ₹158.12
- Asset turnover
- 0.92
- Fixed asset turnover
- 2.32
- Capital intensity
- 0.43
- Debtor days
- 83 days
- Inventory turnover
- 1.33
- Cash conversion cycle
- 232 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹8 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹5,132 Cr |
| Sales | Operating profit | ₹901 Cr |
| Operating profit | Interest | ₹76 Cr |
| Operating profit | Depreciation | ₹277 Cr |
| Operating profit | Profit before tax | ₹548 Cr |
| Other income | Profit before tax | ₹61 Cr |
| Profit before tax | Tax and other | ₹106 Cr |
| Profit before tax | Net profit | ₹503 Cr |
Revenue and net profit
Revenue grew 2.7% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹5,067 Cr | ₹1,097 Cr |
| FY2022 | ₹5,035 Cr | ₹544 Cr |
| FY2023 | ₹5,149 Cr | ₹347 Cr |
| FY2024 | ₹5,874 Cr | ₹666 Cr |
| FY2025 | ₹6,033 Cr | ₹503 Cr |
Cash flows
FY2025: ₹227 Cr from operations, -₹409 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹1,485 Cr | ₹559 Cr |
| FY2022 | ₹545 Cr | ₹176 Cr |
| FY2023 | ₹730 Cr | ₹269 Cr |
| FY2024 | ₹773 Cr | ₹444 Cr |
| FY2025 | ₹227 Cr | -₹409 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹6,033 Cr+2.7%1Y
- Net profit
- ₹503 Cr-24.5%1Y
- Cash from operations
- ₹227 Cr
- Free cash flow
- -₹409 Cr-192.1%1Y
- Revenue CAGR, 5Y
- 7.3%
- EBITDA CAGR, 5Y
- -5.0%
- Net profit CAGR, 5Y
- -7.2%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹6,033 Cr | ₹901 Cr | — | ₹503 Cr | ₹227 Cr | -₹409 Cr | 9.7% | +2.7% | -24.5% |
Monthly returns
Month-by-month returns of APLLTD across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹7,556 Cr |
| Equity capital | ₹39 Cr |
| Reserves | ₹5,155 Cr |
| Borrowings | ₹1,194 Cr |
| Other liabilities | ₹1,168 Cr |
| Assets | ₹7,556 Cr |
| Fixed assets | ₹2,513 Cr |
| Capital work in progress | ₹837 Cr |
| Investments | ₹260 Cr |
| Other assets | ₹3,946 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
APLLTD trades at 35.5x earnings against a peer median of 52.6x (a 33% discount).
Not shown (no positive earnings and no EV / Sales): JUBILANT PHARMOVA LIMITED.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| ALEMBIC PHARMACEUTICALS LIMITEDAPLLTDthis companyP/E ↓ discount | ₹15,765 Cr | 35.5x | 3.0x | 13.6% | 15.2x |
| Ventive Hospitality LimitedVENTIVE | ₹17,846 Cr | 91.9x | 3.9x | 49.7% | 60.7x |
| Poly Medicure LtdPOLYMED | ₹17,352 Cr | 49.8x | 6.0x | 17.3% | 42.5x |
| Cohance Lifesciences LimitedCOHANCE | ₹17,161 Cr | 46.3x | 3.9x | 14.6% | 37.0x |
| JUBILANT PHARMOVA LIMITEDJUBLPHARMA | ₹16,581 Cr | — | 7.4x | 1.3% | 140.4x |
| Dr. Agarwal's Health Care LimitedAGARWALEYE | ₹15,850 Cr | 302.0x | 8.1x | 2.0% | 62.8x |
| Natco Pharma Ltd.NATCOPHARM | ₹15,582 Cr | 10.3x | 1.9x | 23.4% | 8.8x |
| Granules India Ltd.GRANULES | ₹14,372 Cr | 39.7x | 4.0x | 14.0% | 18.5x |
| ACUTAAS CHEMICALS LIMITEDACUTAAS | ₹13,806 Cr | 61.2x | 9.7x | 6.5% | 154.5x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
APLLTD since 1 January, against earlier years.
Historical volatility
APLLTD's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 29.0% |
| FY2022 | 18.0% |
| FY2023 | 13.0% |
| FY2024 | 17.0% |
| FY2025 | 15.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹6,033 Cr |
| Costs | |
| Interest | ₹76 Cr |
| Expenses | ₹5,131 Cr |
| Operating profitOperating Profit | ₹901 Cr |
| Other income and charges | |
| Profit before tax | ₹609 Cr |
| Tax | |
| Net profitNet Profit | ₹503 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹7,556 Cr |
| Equity capitalEquity Capital | ₹39 Cr |
| Reserves | ₹5,155 Cr |
| Borrowings | ₹1,194 Cr |
| Other liabilitiesOther Liabilities | ₹1,168 Cr |
| AssetsTotal Assets | ₹7,556 Cr |
| Fixed assetsFixed Assets | ₹2,513 Cr |
| Capital work in progressCWIP | ₹837 Cr |
| Investments | ₹260 Cr |
| Other assetsOther Assets | ₹3,946 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹227 Cr |
| Investing cash flowCash from Investing Activity | -₹636 Cr |
| Financing cash flowCash from Financing Activity | ₹404 Cr |
| Change in cashNet Cash Flow | -₹6 Cr |
Learn while you research
Academy chapters picked for ALEMBIC PHARMACEUTICALS LIMITED and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 35.5, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read